These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Robak T; Wrzesień-Kuś A Leuk Lymphoma; 2002 Feb; 43(2):281-91. PubMed ID: 11999559 [TBL] [Abstract][Full Text] [Related]
7. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Schlenk RF; Benner A; Hartmann F; del Valle F; Weber C; Pralle H; Fischer JT; Gunzer U; Pezzutto A; Weber W; Grimminger W; Preiss J; Hensel M; Fröhling S; Döhner K; Haas R; Döhner H; Leukemia; 2003 Aug; 17(8):1521-8. PubMed ID: 12886238 [TBL] [Abstract][Full Text] [Related]
8. Drug therapy for acute myeloid leukemia. Tallman MS; Gilliland DG; Rowe JM Blood; 2005 Aug; 106(4):1154-63. PubMed ID: 15870183 [TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia and acute promyelocytic leukemia. Löwenberg B; Griffin JD; Tallman MS Hematology Am Soc Hematol Educ Program; 2003; ():82-101. PubMed ID: 14633778 [TBL] [Abstract][Full Text] [Related]
10. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Kantarjian H Semin Hematol; 1999 Oct; 36(4 Suppl 8):16-25. PubMed ID: 10622225 [TBL] [Abstract][Full Text] [Related]
11. The challenge of acute myeloid leukemia in older patients. Sekeres MA; Stone RM Curr Opin Oncol; 2002 Jan; 14(1):24-30. PubMed ID: 11790976 [TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092 [TBL] [Abstract][Full Text] [Related]
14. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same? Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584 [TBL] [Abstract][Full Text] [Related]
15. Does it matter how remission is achieved in acute leukemia? Bishop JF Leukemia; 1996 Apr; 10 Suppl 1():S7-9. PubMed ID: 8618474 [TBL] [Abstract][Full Text] [Related]
16. Biology and management of relapsed acute myeloid leukaemia. Craddock C; Tauro S; Moss P; Grimwade D Br J Haematol; 2005 Apr; 129(1):18-34. PubMed ID: 15801952 [TBL] [Abstract][Full Text] [Related]
17. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
18. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. Mandelli F; Petti MC; Lo Coco F Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of acute myeloid leukemias in the adult in relapse]. Thomas X; Le QH Bull Cancer; 2002 Sep; 89(9):795-807. PubMed ID: 12368132 [TBL] [Abstract][Full Text] [Related]
20. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W; Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]